title: [Chemohyperthermic peritoneal perfusion and subtotal peritonectomy for peritonitis carcinomatosa in gastroenteric cancer].
abstract: A new operative procedure, called subtotal peritonectomy (SP), in combination with chemohyperthermic peritoneal perfusion, was developed for the treatment of peritonitis carcinomatosa in gastrointestinal cancer. SP includes resection of primary lesion, colon, small bowel, spleen, and gall bladder and parietal peritonectomy. Six patients with gastric cancer and two patients with colon cancer underwent these procedures. A great deal of discharge from the peritoneal cavity, an increase in systemic vascular resistance index, and a decrease in central venous pressure represented much decrease in circulatory volume on days 1 to 2 postoperatively. This state improved at 3 to 4 days after operation. Histopathological study revealed multiple peritoneal seedings with negative surgical margins in all patients. There were no related deaths though bleeding, perforation, and abscess occurred in two patients each. One patient died of peritoneal recurrence after one year, but the other have survived.
authors.affiliation: Second Dept. of Surgery, School of Medicine, Kanazawa University.
authors.forename: T
authors.initials: T
authors.lastname: Fujimura
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: H
authors.initials: H
authors.lastname: Nakagawara
authors.forename: H
authors.initials: H
authors.lastname: Fujita
authors.forename: H
authors.initials: H
authors.lastname: Itoh
authors.forename: Y
authors.initials: Y
authors.lastname: Hirono
authors.forename: S
authors.initials: S
authors.lastname: Kinami
authors.forename: M
authors.initials: M
authors.lastname: Kaji
authors.forename: M
authors.initials: M
authors.lastname: Nakai
authors.forename: S
authors.initials: S
authors.lastname: Fushida
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D010477:Perfusion / Q000379:methods*; D010533:Peritoneal Lavage; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D010537:Peritoneum / Q000601:surgery*; D010538:Peritonitis / Q000601:surgery / Q000628:therapy*; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D016685:Mitomycin; D005047:Etoposide; D002945:Cisplatin